Selux Diagnostics Receives Additional $14.6 Million In Barda Funding After Successfully Completing First Clinical Trial
Selux Diagnostics Receives Additional $14.6 Million In Barda Funding After Successfully Completing First Clinical Trial
06/08/21, 4:25 PM
Location
bostonMoney raised
$14.6 million
Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced that it has been awarded an additional $14.6 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.
Company Info
Location
boston, massachusetts, united states
Additional Info
The proprietary Selux technology uniquely provides targeted therapy results days faster than the current standard of care providing actionable information to inform patient treatment for all Infectious Diseases. Selux's NGP platform provides unprecedented speed-to-results and breadth of menu while meeting the accuracy, throughput, and cost effectiveness requirements of clinical microbiology laboratories and integrated healthcare systems.
Caution - The Selux platform is an investigational device, limited by federal law to investigational use